Loading
SK Life Science
SK Life Science is the American arm of the Korean drug maker SK Biopharmaceuticals, best known for epilepsy medicines. It is now developing a radioactive cancer medicine, SKL35501, aimed at tumours that carry the NTSR1 receptor.
Also called: SK Life Science, Inc.SK Life Sciences Inc.SKLSI
Overview
SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., is based at 461 From Road in Paramus, New Jersey (FDA record) and says it develops treatments for central nervous system disorders and cancer. Its pipeline lists the epilepsy medicine cenobamate and several oncology programmes: SKL35501 (FL-091) targeting NTSR1, a CA9-targeting programme, a ROR1 project and a p300 degrader. It describes a global first-in-human phase 1 trial of SKL35501, an alpha-emitter radiopharmaceutical, in advanced solid tumours expressing NTSR1 in the United States and South Korea (NCT07812805). On 5 October 2026 the FDA granted orphan drug designation for pancreatic cancer to 225Ac chelated with SKL35500, an NTSR1-targeting compound with a DOTA chelator.
Headquarters
Paramus, NJ, US
Scorecard
All companies#664of 1706 companies, score 5
- phase 1/2 +1
- modalities +2
- 24-month regulatory events +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Type
Website
Products
1Phase 1Actinium-225 radioligand (targeted alpha therapy)
SKL35501 is an experimental radioactive medicine from SK Life Science that seeks out tumour cells carrying the NTSR1 receptor and irradiates them from close range. It is in a first trial in people, and the FDA has given it orphan drug status for pancreatic cancer.
Notes
- The FDA record names the product as actinium-225 chelated with the ligand SKL35500; the company lists its NTSR1 alpha-emitter as SKL35501, and OnCo records the designation on that product. SK Biopharmaceuticals itself has no record yet. Read on 4 November 2026.
Connected
5Similar pages
- CompanyAriceum Therapeutics
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
- IdeaA global medical isotope supply observatory with forecasts and shortage alerts
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
- CompanyARTBIO
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
- CompanyChengdu New Radiomedicine Technology
Shares Radioligand therapy (beta emitters), Pancreatic ductal adenocarcinoma.
- CompanyFull-Life Technologies
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
- TechnologyMiniprotein radioconjugates
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
- CompanyAlpha Tau Medical
Shares Targeted alpha therapy, Pancreatic ductal adenocarcinoma.
- TechnologyRadioligand dosimetry
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
cancers
fronts
technologies
drugs
Phase 1Actinium-225 radioligand (targeted alpha therapy)
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
sklifescienceinc.com · 2
ClinicalTrials.gov · 1
US Food and Drug Administration · 1
A source that has moved or gone is reported by the weekly link check. /audit/